← FDA DRUG APPROVALS

FDA ANDA · ANDA090797

PANTOPRAZOLE SODIUM

Sponsor: ACTAVIS TOTOWA

APPLICATION
ANDA090797
TYPE
ANDA
ORIGINAL APPROVAL
2011-02-07
LATEST ACTION
2024-03-13
ROUTE
ORAL
DOSAGE FORM
TABLET, DELAYED RELEASE
MARKETING STATUS
Discontinued

Products

PANTOPRAZOLE SODIUMDiscontinued
PANTOPRAZOLE SODIUM EQ 20MG BASE · TABLET, DELAYED RELEASE · ORAL
PANTOPRAZOLE SODIUMDiscontinued
PANTOPRAZOLE SODIUM EQ 40MG BASE · TABLET, DELAYED RELEASE · ORAL

Approval history

2024-03-13Labeling · Supplement 14 · standardAP
2024-03-13Labeling · Supplement 12 · standardAP
2024-03-13Labeling · Supplement 15 · standardAP
2024-03-13Labeling · Supplement 13 · standardAP
2015-04-09Labeling · Supplement 11 · standardAP
2014-12-10Labeling · Supplement 10 · standardAP
2014-12-10Labeling · Supplement 9 · standardAP
2013-05-30Labeling · Supplement 7 · standardAP
2013-05-30Labeling · Supplement 6 · standardAP
2012-03-23Labeling · Supplement 4AP
2011-02-07OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →